Yttrium-90 radioembolization for hepatocellular carcinoma

Ryan M Hickey, Robert J Lewandowski, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

90Y radioembolization refers to the selective, transcatheter, and intra-arterial injection of micrometer-sized particles loaded with the radioisotope yttrium-90 for the treatment of primary and metastatic hepatic malignancies. In the treatment of intermediate- and advanced-stage hepatocellular carcinoma, 90Y radioembolization provides favorable outcomes with minimal side effects, offering an alternative treatment option to other transarterial therapies, such as bland embolization and chemoembolization. This review provides an overview of the use of 90Y radioembolization in the treatment of hepatocellular carcinoma, including patient selection criteria, dosimetry, and clinical outcomes.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalSeminars in Nuclear Medicine
Volume46
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Yttrium
Hepatocellular Carcinoma
Yttrium Radioisotopes
Patient Selection
Intra-Arterial Injections
Therapeutics
Liver
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{c8637881814248ad8a781bcdee569a02,
title = "Yttrium-90 radioembolization for hepatocellular carcinoma",
abstract = "90Y radioembolization refers to the selective, transcatheter, and intra-arterial injection of micrometer-sized particles loaded with the radioisotope yttrium-90 for the treatment of primary and metastatic hepatic malignancies. In the treatment of intermediate- and advanced-stage hepatocellular carcinoma, 90Y radioembolization provides favorable outcomes with minimal side effects, offering an alternative treatment option to other transarterial therapies, such as bland embolization and chemoembolization. This review provides an overview of the use of 90Y radioembolization in the treatment of hepatocellular carcinoma, including patient selection criteria, dosimetry, and clinical outcomes.",
author = "Hickey, {Ryan M} and Lewandowski, {Robert J} and Riad Salem",
year = "2016",
month = "3",
day = "1",
doi = "10.1053/j.semnuclmed.2015.10.011",
language = "English (US)",
volume = "46",
pages = "105--108",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Yttrium-90 radioembolization for hepatocellular carcinoma. / Hickey, Ryan M; Lewandowski, Robert J; Salem, Riad.

In: Seminars in Nuclear Medicine, Vol. 46, No. 2, 01.03.2016, p. 105-108.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Yttrium-90 radioembolization for hepatocellular carcinoma

AU - Hickey, Ryan M

AU - Lewandowski, Robert J

AU - Salem, Riad

PY - 2016/3/1

Y1 - 2016/3/1

N2 - 90Y radioembolization refers to the selective, transcatheter, and intra-arterial injection of micrometer-sized particles loaded with the radioisotope yttrium-90 for the treatment of primary and metastatic hepatic malignancies. In the treatment of intermediate- and advanced-stage hepatocellular carcinoma, 90Y radioembolization provides favorable outcomes with minimal side effects, offering an alternative treatment option to other transarterial therapies, such as bland embolization and chemoembolization. This review provides an overview of the use of 90Y radioembolization in the treatment of hepatocellular carcinoma, including patient selection criteria, dosimetry, and clinical outcomes.

AB - 90Y radioembolization refers to the selective, transcatheter, and intra-arterial injection of micrometer-sized particles loaded with the radioisotope yttrium-90 for the treatment of primary and metastatic hepatic malignancies. In the treatment of intermediate- and advanced-stage hepatocellular carcinoma, 90Y radioembolization provides favorable outcomes with minimal side effects, offering an alternative treatment option to other transarterial therapies, such as bland embolization and chemoembolization. This review provides an overview of the use of 90Y radioembolization in the treatment of hepatocellular carcinoma, including patient selection criteria, dosimetry, and clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84958779419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958779419&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2015.10.011

DO - 10.1053/j.semnuclmed.2015.10.011

M3 - Review article

C2 - 26897714

AN - SCOPUS:84958779419

VL - 46

SP - 105

EP - 108

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 2

ER -